Instil Bio, Inc. (TIL)
NASDAQ: TIL · IEX Real-Time Price · USD
11.50
-0.30 (-2.54%)
At close: May 17, 2024, 4:00 PM
11.28
-0.22 (-1.91%)
After-hours: May 17, 2024, 4:06 PM EDT
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer.
It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | (972) 499-3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer |
| Dr. Robert Hawkins MBBS, Ph.D. | Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |